Dichlorobis(triphenylphosphine)palladium

This chemical does not meet GHS hazard criteria for 19.7% (46 of 233) of reports.

Warning

H302 (18.5%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P272, P273, P280, P301+P317, P302+P352, P305+P351+P338, P321, P330, P332+P317, P333+P317, P337+P317, P362+P364, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 233 reports by companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Status: Active Update: 11-01-2022 https://echa.europa.eu/registration-dossier/-/registered-dossier/18826

Bis(triphenylphosphine)palladium (II) chloride: Does not have an individual approval but may be used under an appropriate group standard

Due to their ability to form strong complexes with both inorganic and organic ligands, palladium ions can disturb cellular equilibria, replace other essential ions, and interact with functional groups of macromolecules, such as proteins or DNA. Palladium complexes binding to DNA and RNA leads to strand breakage. Palladium ions are able to inhibit most major cellular functions, including DNA and RNA synthesis. Palladium compounds have been shown to bind to and inhibit various enzymes, including creatine kinase and prolyl hydroxylase. (L798)

Palladium may be absorbed through oral, dermal, and inhalation exposure. Once in the body it distributes to the kidney, liver, spleen, lymph nodes, adrenal gland, lung and bone. Palladium's ability to form complexes allows it the bind to amino acids, proteins, DNA, and other macromolecules. Palladium and its metabolites are excreted in the urine and faeces. (A21)